CTLA4 and melanoma: In a recent retrospective analysis of over 40,000 patients in the FDA Adverse Event Reporting System, the incidence of ICI-induced uveitis was established to be 0.45% among patients taking anti-PD-1/anti-PD-L1, anti-CTLA-4, or anti-PD-1/anti-CTLA-4 combination, all doses and durations combined, while this was almost three times higher, at 1.2%, in patients with melanoma [71].